Founder & CEO · QADR Biotechnology Group

Two decades backing companies. Now I build them — on a fraction of the capital.

QADR pairs a clinical-stage microbiome biotech with revenue-generating wellness brands. I run all of it as sole founder, on an AI-native operating stack. The capital efficiency is the strategy — not a constraint.

The operating thesis

Why this is built the way it is
Capital efficiency

Efficiency is the strategy

One founder. Roughly nineteen integrated systems. The work that conventionally requires an operating team runs on automation I designed, built, and own — so capital goes into science and inventory, not headcount.

Structure

Consumer revenue, clinical upside

The wellness brands generate cash and validate the microbiome thesis in-market. The biotech carries the asymmetric return. Each side de-risks the other.

Platform

One platform, many brands

Shared commerce, CRM, and workflow infrastructure across the portfolio. Every new brand inherits a machine that already works — launch cost trends toward zero.

Operating model
Aziz El Messaoudi Founder — 1 FTE
ShopifyLiquid OS 2.0Klaviyo n8nNotionSupabase VercelRechargeAirtable SlackStripeHubSpot GmailDriveJudge.me AfterShipBenchlingQuickBooks Claude
19 integrated systems · automated workflows
GutRecover Therapeutics Stryō Muihā Microbiomae

Where an org chart would show headcount, this shows systems. That substitution is the entire investment case.

Track record

Twenty years, both sides of the table
2026 — Founder & CEO QADR Biotechnology Group · biotech & wellness holding
2014 — Partner Eizmann & Associates · venture capital & private equity, New York
2009 — Founder & CEO Eizmann Group · global private equity, Switzerland
2005–2009 Business Unit Director Intermarché / ITM · multi-unit P&L, France
2003–2005 Deputy Manager Bricomarché · France
2002–2003 Sales & Marketing Dell EMC · Geneva

Disclosure — Eizmann Group operates independently of QADR Biotechnology. There are no cross-holdings, participations, or commercial arrangements between them.

Story

From the other side of the table
Aziz El Messaoudi

I spent twenty years evaluating other people's companies — private equity, venture capital, corporate strategy. You learn quickly what separates a business that compounds from one that merely grows: how much it has to spend to prove it works.

Eventually the analysis stopped being enough. I wanted to be on the other side of the table.

So I built the company I would have backed.

QADR is a bet that the gut microbiome is the next frontier in human health — and that the fastest, cheapest way to prove it is to run the science and the commerce under one roof. GutRecover pursues the clinical thesis. The wellness brands fund it, validate demand, and reach people today.

What makes it unusual is the operating model. There is no team behind me — there is a system. I designed and built the entire stack myself: commerce, CRM, automation, content, finance. Nineteen integrated tools doing the work an operating team would otherwise do. It's not a staffing gap. It's the edge.

The scientific and clinical team is being assembled around GutRecover as it advances toward the clinic.

I document the build

The operating model, the systems, and the microbiome thesis — written and filmed as it happens, not in retrospect.

Follow on LinkedIn
Open to investor conversations

Building the company I'd have backed.

For investors, strategic partners, and operators working the same way — I read every note personally.